Wednesday, November 16, 2011
Mirna Therapeutics Inc., of Austin, Texas, presented preclinical data showing that mimics of five tumor suppressor miRNAs, including miR-34 and let-7, significantly inhibited the growth of liver tumors compared to controls. The five miRNA mimics were complexed with a lipid nanoparticle delivery formulation and were found to be neither toxic nor immunostimulatory. Additional preclinical work is ongoing.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.